Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.97 HKD | +3.12% | +16.93% | -55.27% |
Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.27% | 356M | |
+55.55% | 59.28B | |
+43.17% | 40.94B | |
-4.71% | 40.17B | |
-5.56% | 28.69B | |
+13.76% | 26.63B | |
-22.00% | 18.89B | |
+31.50% | 12.46B | |
+2.16% | 12.42B | |
+25.70% | 12.26B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting